Myriad Genetics announced that the United States Patent and Trademark Office has issued a patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease, or MRD, assay to market. U.S. patent 11,932,910, entitled Combinatorial DNA Screening, covers Myriad’s foundational and proprietary method of preparing cell free DNA. This method describes a key aspect of tumor-informed MRD assays that detect circulating tumor DNA through sequencing. Specifically, the patented method relates to the manner in which a sample is sufficiently enriched with ctDNA that it can be detected, if present, with high sensitivity and specificity.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
- Myriad Genetics announces patent granted for SneakPeek Snap device
- Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
- Myriad Genetics price target raised to $28 from $25 at Raymond James
- Myriad Genetics price target raised to $26 from $23 at TD Cowen